SG11201504372UA - A method of purifying therapeutic proteins - Google Patents

A method of purifying therapeutic proteins

Info

Publication number
SG11201504372UA
SG11201504372UA SG11201504372UA SG11201504372UA SG11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA
Authority
SG
Singapore
Prior art keywords
therapeutic proteins
purifying therapeutic
purifying
proteins
therapeutic
Prior art date
Application number
SG11201504372UA
Other languages
English (en)
Inventor
Hung Pham
Jeffrey Michael Hey
Darren Nguy
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of SG11201504372UA publication Critical patent/SG11201504372UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/363Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
SG11201504372UA 2012-12-05 2013-12-05 A method of purifying therapeutic proteins SG11201504372UA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261733761P 2012-12-05 2012-12-05
EP13153898 2013-02-04
US13/803,740 US20140154233A1 (en) 2012-12-05 2013-03-14 Method of purifying therapeutic proteins
AU2013203357A AU2013203357B2 (en) 2012-12-05 2013-04-10 A method of purifying therapeutic proteins
PCT/AU2013/001414 WO2014085861A1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Publications (1)

Publication Number Publication Date
SG11201504372UA true SG11201504372UA (en) 2015-07-30

Family

ID=47630209

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704484QA SG10201704484QA (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins
SG11201504372UA SG11201504372UA (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201704484QA SG10201704484QA (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Country Status (13)

Country Link
US (5) US20140154233A1 (ja)
EP (2) EP3483173A1 (ja)
JP (2) JP6411360B2 (ja)
KR (2) KR102240978B1 (ja)
CN (2) CN104981476B (ja)
AU (2) AU2013203357B2 (ja)
BR (1) BR112015012854B1 (ja)
CA (2) CA3185085A1 (ja)
HK (1) HK1214833A1 (ja)
PL (1) PL2928905T3 (ja)
RU (1) RU2685956C2 (ja)
SG (2) SG10201704484QA (ja)
WO (1) WO2014085861A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013135684A1 (en) 2012-03-13 2013-09-19 Octapharma Ag Improved process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
US20180369346A1 (en) * 2016-01-07 2018-12-27 Eio Biomedical Ltd. Methods, compositions and kits for reducing tissue adhesions
WO2018042438A2 (en) * 2016-09-01 2018-03-08 Plas-Free Ltd Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
BR112020002234A2 (pt) * 2017-08-23 2020-07-28 Csl Behring Gmbh método para a filtragem de virus do fator von willebrand
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
JP2024513983A (ja) 2021-04-13 2024-03-27 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 第viii因子または第viii因子/フォン・ヴィレブランド因子複合体を含む液体組成物
CN115181178B (zh) * 2021-09-04 2024-04-26 广东双林生物制药有限公司 一种从冷沉淀中制备人纤维蛋白原的方法
US20230210958A1 (en) 2021-12-30 2023-07-06 Baxter International Inc. Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
WO1993005067A1 (en) * 1991-09-05 1993-03-18 Baxter International, Inc. Topical fibrinogen complex
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
ES2139227T5 (es) 1994-07-14 2011-05-04 Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación.
WO1996007728A1 (en) * 1994-09-02 1996-03-14 New York Blood Center, Inc. Production and secretion of recombinant fibrinogen by yeast
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
AU6104799A (en) * 1998-09-24 2000-04-10 Ppl Therapeutics (Scotland) Limited Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography
AU5441101A (en) 1999-12-23 2001-07-03 Rodger H. Rast System and method for providing individualized dosing
NZ518692A (en) 1999-12-23 2004-08-27 Csl Ltd Purified fibrinogen free of destabilising levels of plasminogen and other proteases obtained from a Fraction I paste
WO2002095019A1 (en) * 2001-05-21 2002-11-28 Omrix Biopharmaceuticals S.A. Removal of plasmin(ogen) from protein solutions
AUPR638801A0 (en) 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
EP1450829A1 (en) * 2001-10-03 2004-09-01 Christopher J. Woolverton Storage-stable fibrinogen solutions
AU2002340776A1 (en) * 2001-10-30 2003-05-12 Novozymes A/S High throughput isolation of proteins by charge induction chromatography
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JP4319979B2 (ja) * 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
DE102004009400A1 (de) * 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
US20070142629A1 (en) * 2004-06-16 2007-06-21 Ciphergen Biosystems, Inc. Multichemistry fractionation
ATE546520T1 (de) * 2007-01-04 2012-03-15 Crucell Holland Bv Faktor-xi-reinigung
AU2008274195B2 (en) 2007-07-11 2013-09-05 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
KR20100103595A (ko) 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 비-글라이코실화된 단백질의 정제
KR101700722B1 (ko) * 2008-06-24 2017-01-31 옥타파마 아게 응고 인자 viii을 정제하는 방법
US20130011382A1 (en) * 2010-01-08 2013-01-10 Profibrix Bv Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain
CN103328503B (zh) 2010-09-20 2016-08-24 欧克塔医药公司 纤维蛋白原生产方法
EP2649087A1 (en) * 2010-12-08 2013-10-16 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
WO2013135684A1 (en) 2012-03-13 2013-09-19 Octapharma Ag Improved process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Also Published As

Publication number Publication date
CN104981476A (zh) 2015-10-14
RU2685956C2 (ru) 2019-04-23
EP2928905A1 (en) 2015-10-14
BR112015012854B1 (pt) 2021-11-30
CN104981476B (zh) 2018-10-09
KR20150090252A (ko) 2015-08-05
CN109125714B (zh) 2022-08-02
RU2015126551A (ru) 2017-01-10
US20210283530A1 (en) 2021-09-16
US20150158906A1 (en) 2015-06-11
EP3483173A1 (en) 2019-05-15
BR112015012854A2 (pt) 2017-07-11
CA3185085A1 (en) 2014-06-12
JP2016501878A (ja) 2016-01-21
JP6411360B2 (ja) 2018-10-24
JP6836562B2 (ja) 2021-03-03
AU2013203357A1 (en) 2014-06-19
EP2928905A4 (en) 2016-06-08
US20190209948A1 (en) 2019-07-11
JP2019011346A (ja) 2019-01-24
US20170143805A1 (en) 2017-05-25
KR20210042422A (ko) 2021-04-19
WO2014085861A1 (en) 2014-06-12
KR102403847B1 (ko) 2022-05-31
EP2928905B1 (en) 2018-11-21
AU2013354899B2 (en) 2018-05-17
US9598461B2 (en) 2017-03-21
US11426680B2 (en) 2022-08-30
SG10201704484QA (en) 2017-07-28
HK1214833A1 (zh) 2016-08-05
CN109125714A (zh) 2019-01-04
US20140154233A1 (en) 2014-06-05
KR102240978B1 (ko) 2021-04-19
PL2928905T3 (pl) 2019-05-31
AU2013203357B2 (en) 2015-08-27
AU2013354899A1 (en) 2015-07-16
CA2893373A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
HK1214833A1 (zh) 種純化治療性蛋白質的方法
HRP20181357T1 (hr) Novi postupci pročišćavanja proteina
HK1219964A1 (zh) 治療性蛋白藥物物質的整合連續製造
EP2883882A4 (en) PROCESS FOR PURIFYING PROTEINS
GB201217772D0 (en) Sequencing method
EP2720719A4 (en) METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
HK1192587A1 (zh) 治療性融合蛋白
EP2773754A4 (en) Methods of Treatment
GB201110095D0 (en) Method of treatment
HK1212995A1 (zh) 種純化蛋白質的方法
EP2727930A4 (en) PROCESS FOR CLEANING PROTEINS
ZA201502595B (en) Therapeutic methods
HK1216504A1 (zh) 疾病的治療方法
GB201209082D0 (en) Purification method
HK1211789A1 (en) Plants for production of therapeutic proteins
EP2762486A4 (en) PROCESS FOR PURIFYING PROTEIN
SG10201911709RA (en) A method of purifying therapeutic proteins
EP2791324A4 (en) PROCESSING METHOD
GB201215435D0 (en) Sequencing method
GB201217173D0 (en) Therapeutic method
EP2814499A4 (en) PURIFICATION PROCESS
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201111530D0 (en) Method of treatment
GB201109509D0 (en) Method of treatment